Jun 01 2021 Opposition to a second Japanese patent, applied for in relation to the use of CRISPR methods in cellular studies, has been rejected by the Japanese Patent Office (JPO), reports ERS Genomics, the Dublin-based company providing access to this technology. “The JPO actions reinforce the broad and fundamental nature of our CRISPR patent portfolio, both in Japan and worldwide.” Michael Arciero Japanese patent (JP6692856), filed by CRISPR/Cas9 intellectual property co-owner Dr. Emannuelle Charpentier, together with The Regents of the University of California and University of Vienna (collectively known as CVC), covers compositions and methods for use in a variety of eukaryotic cells, in either dual-guide or single-guide format.